Welcome to our dedicated page for Integer Hldgs news (Ticker: ITGR), a resource for investors and traders seeking the latest updates and insights on Integer Hldgs stock.
Integer Holdings Corporation reports news as a medical device contract development and manufacturing organization serving cardio and vascular, neuromodulation, and cardiac rhythm management markets. Company updates commonly cover sales trends, organic growth, product-line performance, adjusted earnings measures, debt and leverage, and outlook commentary tied to customer programs and new product activity.
Integer news also includes governance and capital-allocation developments, including board composition, shareholder engagement, share repurchase authorization, investor conference participation, and broader strategy updates. The company’s public identity includes the Greatbatch Medical and Lake Region Medical brands and engineering and manufacturing work for medical device customers.
Integer Holdings Corporation (NYSE: ITGR) has announced a successful refinancing of its debt through the establishment of $1 billion in Senior Secured Credit Facilities. The new five-year $400 million Revolving Credit Facility, $250 million Term Loan A, and seven-year $350 million Term Loan B are expected to enhance operational flexibility and reduce borrowing costs. This transaction will improve future annualized diluted earnings per share by approximately $0.15 and extend the nearest debt maturity from 2022 to 2026.
Both Moody's and S&P upgraded the company's credit ratings to Ba3/BB- following this restructuring.
Integer Holdings Corporation (NYSE: ITGR) will showcase its innovative medical device outsourcing capabilities at the MD&M West Exposition in Anaheim, California, from August 10-12, 2021. At booth #2951, Integer will highlight its advanced Xcellion® Rechargeable Batteries, which reduce charging time by up to 70% and increase runtime by 30%. The company will also present its expanded laser cutting capabilities and comprehensive lead solutions. Integer emphasizes its commitment to quality and innovation in the medical device industry.
Integer Holdings Corporation (NYSE:ITGR) reported a strong financial performance for Q2 2021, with sales increasing by 30% to $312 million. GAAP net income rose by $29 million, reaching $29 million, while non-GAAP adjusted net income surged by 239% to $36 million. The company reduced total debt by $63 million to $669 million, achieving a leverage ratio of 3.1 times adjusted EBITDA. Looking ahead, Integer has raised its full-year sales growth outlook to 12-14% and expects adjusted operating income growth between 25-36%, signaling a robust recovery from the pandemic.
Integer Holdings Corporation (NYSE:ITGR) will announce its second quarter 2021 financial results on July 29, 2021, at 7 a.m. CT. A conference call will follow at 8 a.m. CT to discuss the results and other relevant information. Investors can participate through a domestic or international dial-in and access the webcast online. The company, a leading medical device manufacturer, aims to provide innovative technologies in various medical fields. Further information and updates can be found on their investor relations website.
Integer Holdings Corporation (NYSE:ITGR) reported its Q1 2021 results, with sales of $290 million, a 12% decline from the previous year. GAAP net income fell 31% to $22 million. Despite the pandemic's impact, sales and profits showed sequential improvement compared to Q4 2020. Integer is increasing its 2021 outlook, projecting 10%-12% sales growth, along with $90 million to $110 million in free cash flow. The company's total debt decreased by $25 million to $664 million, reflecting ongoing recovery and strategic execution.
Integer Holdings Corporation (NYSE:ITGR) announces its first quarter 2021 financial results release set for April 29, 2021, at 8 a.m. ET. The management will discuss these results in a conference call at 9 a.m. ET the same day. Investors can access the call via domestic and international dial-in numbers or through a webcast. Integer is a leading medical device outsource manufacturer, focusing on various markets including cardiac and orthopedics, and will also provide updates on additional forward-looking information during the call.
Integer Holdings Corporation (NYSE:ITGR) reported strong fourth quarter results with sales of $269 million, slightly above guidance but a 17% decline year-over-year. GAAP net income rose 40% to $15 million, while adjusted net income fell 43% to $23 million. The company reduced net total debt by $123 million in 2020, ending the year with $689 million in debt. For 2021, Integer projected sales growth of 8% to 12%, with first quarter sales expected to be sequentially better than Q4 2020. The company's operational excellence strategy aims for a return to profitable growth.
Integer Holdings Corporation has elected three new directors to its Board: Sheila Antrum, Cheryl Capps, and Alvin (Tyrone) Jeffers, enhancing its manufacturing and healthcare expertise. Antrum brings over 40 years in medical operations, currently serving as COO at UCSF Health. Capps, with 35 years in supply chain management, is the SVP at Corning Inc. Jeffers, with 24 years in manufacturing, is VP of Global Manufacturing at SPX FLOW. Integer aims to leverage their diverse perspectives to drive growth and execute strategic initiatives.
Integer Holdings Corporation (NYSE:ITGR) is set to announce its financial and operational results for Q4 and full-year 2020 on February 18, 2021, at 8 a.m. ET. A conference call will follow at 9 a.m. ET, where management will discuss the results and other material information. Interested parties can participate via a domestic dial-in number or an international number. A replay of the call will be available for seven days post-event, and the call will also be accessible on the company's Investor Relations website.
Integer Holdings Corporation (NYSE: ITGR) has announced a significant expansion at its Alden, NY facility to increase production capacity for Xcellion® Lithium Ion rechargeable batteries. The expansion, which began in December 2020, aims to enhance battery production for applications in neuromodulation and cochlear devices. The project includes new manufacturing equipment and facility upgrades, expected to complete in 2021. This strategic investment is designed to meet the growing demands of Integer's cardiac and neuromodulation customers.